GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » Effective Interest Rate on Debt %

JAGX (Jaguar Health) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Jaguar Health's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was $0.00 Mil. Jaguar Health's average total debt for the quarter that ended in Dec. 2024 was $35.40 Mil. Therefore, Jaguar Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 0.00%.


Jaguar Health Effective Interest Rate on Debt % Historical Data

The historical data trend for Jaguar Health's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health Effective Interest Rate on Debt % Chart

Jaguar Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.49 36.95 39.64 17.75 0.63

Jaguar Health Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 6.93 - - -

Competitive Comparison of Jaguar Health's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Jaguar Health's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Effective Interest Rate on Debt % falls into.


;
;

Jaguar Health Effective Interest Rate on Debt % Calculation

Jaguar Health's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  -0.231/( (37.094+36.526)/ 2 )
=-1  *  -0.231/36.81
=0.63 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=31.879 + 5.215
=37.094

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=24.189 + 12.337
=36.526

Jaguar Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2024 )+Total Debt  (Q: Dec. 2024 ))/ count )
=-1  *  0/( (34.269+36.526)/ 2 )
=-1  *  0/35.3975
=0.00 %

where

Total Debt  (Q: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.414 + 11.855
=34.269

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=24.189 + 12.337
=36.526

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Jaguar Health  (NAS:JAGX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Jaguar Health Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jaguar Health Business Description

Industry
Traded in Other Exchanges
N/A
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Executives
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi officer: Chief Scientific Officer C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte director, officer: CEO & President 213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak officer: Chief Accounting Officer 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski director C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin officer: Chief of Staff, CCO & GC 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel director C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994 10 percent owner 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow 10 percent owner THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd 10 percent owner PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser 10 percent owner 11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan director C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis director 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson director C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p. 10 percent owner 280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017

Jaguar Health Headlines

From GuruFocus